Brain Mind Center

Warnings: Chantix (varenicline)

In March 2015 the U.S. Food and Drug Administration (FDA) expanded its warnings of adverse effects of the "smoking cessation" drug Chantix (varenicline)

Chantix is a prescription medicine that is FDA-approved to help adults quit smoking.

The FDA bulletin stated: "We reviewed the case series submitted by Pfizer, the manufacturer of Chantix, as well as the cases in the FDA Adverse Event Reporting System (FAERS) database describing patients who drank alcohol during treatment with Chantix and experienced adverse reactions. Some patients experienced decreased tolerance to alcohol, including increased drunkenness, unusual or aggressive behavior, or they had no memory of things that happened. We also reviewed FAERS and the medical literature for cases of seizures with Chantix and identified cases in which the patients who had seizures while taking Chantix either had no history of seizures or had a seizure disorder that had been well-controlled. In most of these cases, the seizures occurred within the first month of starting Chantix. We updated the Warnings and Precautions section of the Chantrix label to include information about several studies that investigated the risk of neuropsychiatric side effects on mood, behavior, or thinking occurring with Chantix.


Further reading: Neuroscience Notes, Intelligence and Learning, Language & Thinking

Persona Digital

Persona Digital Books is the publisher of The Human Brain, Neuroscience Notes, Intelligence & Learning and related books. Three books are available as print editions for mail delivery. All books are available as eBooks for download (PDF files).

Alpha Online Orders... Logon or Create Account | Order Help